Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Over the last 12 months, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $26.09M worth of Ionis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $13.21M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $12,520 was made by KLEIN JOSEPH III (director) on 2006‑08‑15.
2024-06-17 | Sale | BERTHELSEN SPENCER R | director | 16,000 0.0111% | $40.29 | $644,640 | +2.63% | |
2024-05-03 | Sale | KLEIN JOSEPH III | director | 6,000 0.0042% | $42.71 | $256,277 | -5.96% | |
2024-04-16 | Sale | Birchler Brian | EVP, Corp and Development Ops | 905 0.0006% | $41.66 | $37,698 | -2.81% | |
2024-04-16 | Sale | Baroldi Joseph | EVP, Chief Business Officer | 4,006 0.0028% | $41.60 | $166,641 | -2.81% | |
2024-02-16 | Sale | Monia Brett P | Chief Executive Officer | 387 0.0003% | $44.49 | $17,219 | -5.51% | |
2024-02-02 | Sale | Monia Brett P | Chief Executive Officer | 23,501 0.0156% | $49.37 | $1.16M | -15.01% | |
2024-02-02 | Sale | HOUGEN ELIZABETH L | EVP, Finance & CFO | 2,125 0.0014% | $49.54 | $105,272 | -15.01% | |
2024-02-02 | Sale | Geary Richard S | EVP, Chief Development Officer | 1,961 0.0013% | $50.04 | $98,135 | -15.01% | |
2024-02-02 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 1,853 0.0012% | $49.52 | $91,752 | -15.01% | |
2024-02-02 | Sale | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 2,071 0.0014% | $49.59 | $102,701 | -15.01% | |
2024-02-02 | Sale | O'NEIL PATRICK R. | EVP CLO & General Counsel | 1,961 0.0013% | $49.67 | $97,410 | -15.01% | |
2024-02-02 | Sale | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | 2,125 0.0014% | $49.60 | $105,404 | -15.01% | |
2024-02-02 | Sale | Swayze Eric | EVP Research | 1,907 0.0013% | $49.56 | $94,513 | -15.01% | |
2024-01-31 | Sale | Swayze Eric | EVP Research | 10,773 0.0075% | $52.00 | $560,196 | -17.53% | |
2024-01-25 | Sale | Monia Brett P | Chief Executive Officer | 2,285 0.0016% | $51.75 | $118,249 | -17.04% | |
2024-01-25 | Sale | O'NEIL PATRICK R. | EVP CLO & General Counsel | 6,450 0.0045% | $51.75 | $333,788 | -17.04% | |
2024-01-17 | Sale | Monia Brett P | Chief Executive Officer | 32,059 0.022% | $50.42 | $1.62M | -16.33% | |
2024-01-17 | Sale | HOUGEN ELIZABETH L | EVP, Finance & CFO | 8,683 0.006% | $50.42 | $437,771 | -16.33% | |
2024-01-17 | Sale | Geary Richard S | EVP, Chief Development Officer | 7,338 0.005% | $50.42 | $369,960 | -16.33% | |
2024-01-17 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 6,745 0.0046% | $50.42 | $340,063 | -16.33% |
Monia Brett P | Chief Executive Officer | 173751 0.1214% | $47.70 | 0 | 51 | |
BERTHELSEN SPENCER R | director | 147257 0.0704% | $47.70 | 0 | 8 | |
HOUGEN ELIZABETH L | EVP, Finance & CFO | 92905 0.0648% | $47.70 | 0 | 32 | |
Geary Richard S | EVP, Chief Development Officer | 87334 0.0609% | $47.70 | 0 | 54 | |
PARSHALL B LYNNE | director | 82588 0.0576% | $47.70 | 0 | 97 | |
BENNETT C FRANK | EVP, Chief Scientific Officer | 79079 0.0551% | $47.70 | 0 | 75 | |
Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 49812 0.0347% | $47.70 | 0 | 6 | |
O'NEIL PATRICK R. | EVP CLO & General Counsel | 48661 0.0339% | $47.70 | 0 | 75 | |
Birchler Brian | EVP, Corp and Development Ops | 46156 0.0311% | $47.70 | 0 | 3 | |
Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | 35825 0.025% | $47.70 | 0 | 5 | |
Swayze Eric | EVP Research | 34324 0.0239% | $47.70 | 0 | 10 | |
KLEIN JOSEPH III | director | 0 0.0114% | $47.70 | 9 | 34 | +49.6% |
Diaz Allene M. | director | 12676 0.0088% | $47.70 | 0 | 1 | |
Baroldi Joseph | EVP, Chief Business Officer | 19631 0.0011% | $47.70 | 0 | 4 | |
GABRIELI CHRISTOPHER | director | 155431 0.1083% | $47.70 | 0 | 19 | |
WENDER JOSEPH H | director | 58916 0.0411% | $47.70 | 0 | 14 | |
MUTO FREDERICK T | director | 31683 0.0221% | $47.70 | 0 | 9 | |
Castleman Breaux | director | 15183 0.0106% | $47.70 | 0 | 1 | |
COLE DOUGLAS L | Vice President | 9616 0.0067% | $47.70 | 0 | 3 | |
Boyce Sarah | Chief Business Officer | 8931 0.0062% | $47.70 | 0 | 3 | |
Wedel Mark K | VP & Chief Medical Officer | 6603 0.0046% | $47.70 | 0 | 5 | |
LUNDSTEDT KAREN S | Vice President | 5407 0.0038% | $47.70 | 0 | 4 | |
BROWN RICHARD K | Vice President | 2348 0.0016% | $47.70 | 0 | 11 | |
CROOKE STANLEY T | Exec Chairman of the Board | 2021 0.0014% | $47.70 | 0 | 170 | |
LEVIN ARTHUR A | Vice President | 1674 0.0012% | $47.70 | 0 | 13 | |
LOWENSTAM PATRICIA | Vice President | 603 0.0004% | $47.70 | 0 | 8 | |
REED JOHN C | director | 0 0% | $47.70 | 0 | 4 | |
ECKER DAVID J | Vice President | 0 0% | $47.70 | 0 | 21 | |
DE HAAN HANS A | VP, Drug Development | 0 0% | $47.70 | 0 | 1 | |
Treble Michael J | Vice President, Pres of Ibis | 0 0% | $47.70 | 0 | 5 |
Fidelity Investments | $947.75M | 14.98 | 21.86M | +1.59% | +$14.82M | 0.06 | |
The Vanguard Group | $582.21M | 9.2 | 13.43M | -5.44% | -$33.51M | 0.01 | |
T Rowe Price Investment Management Inc | $577.3M | 9.12 | 13.32M | +0.88% | +$5.01M | 0.35 | |
BlackRock | $423.61M | 6.7 | 9.77M | +7.89% | +$30.97M | 0.01 | |
Bellevue Group | $359.78M | 5.69 | 8.3M | -4.76% | -$17.97M | 5.49 | |
Wellington Management Company | $246.91M | 3.9 | 5.7M | +23.36% | +$46.76M | 0.04 | |
ClearBridge Investments | $193.61M | 3.06 | 4.47M | -5.13% | -$10.46M | 0.15 | |
State Street | $180.15M | 2.85 | 4.16M | +3.66% | +$6.37M | 0.01 | |
T. Rowe Price | $152.69M | 2.41 | 3.52M | -17.22% | -$31.77M | 0.02 | |
TWEEDY, BROWNE COMPANY LLC | $149.76M | 2.37 | 3.45M | 0% | +$0 | 7.08 | |
Macquarie Group | $138.75M | 2.19 | 3.2M | +3.64% | +$4.87M | 0.11 | |
Bvf Inc Il | $105.28M | 1.66 | 2.43M | 0% | +$0 | 0.77 | |
Geode Capital Management | $102.51M | 1.62 | 2.36M | +3.88% | +$3.83M | 0.01 | |
OrbiMed | $87.26M | 1.38 | 2.01M | -2.51% | -$2.24M | 1.78 | |
ARK Investment Management LLC | $60.68M | 0.96 | 1.4M | -26.52% | -$21.9M | 0.42 | |
Deep Track Capital Lp | $59.54M | 0.94 | 1.37M | +9.96% | +$5.39M | 0.27 | |
Charles Schwab | $56.41M | 0.89 | 1.3M | +2.04% | +$1.13M | 0.01 | |
Morgan Stanley | $50.44M | 0.8 | 1.16M | +6.73% | +$3.18M | <0.01 | |
Two Sigma | $46.99M | 0.74 | 1.08M | +35.24% | +$12.24M | 0.08 | |
Two Sigma Advisers LP | $45.09M | 0.71 | 1.04M | +33.86% | +$11.41M | 0.08 | |
Adage Capital Partners Gp L L C | $43.35M | 0.69 | 1M | -27.81% | -$16.7M | 0.08 | |
Candriam S C A | $39.53M | 0.63 | 911,897 | +44.96% | +$12.26M | 0.26 | |
Td Asset Management Inc | $38.94M | 0.62 | 898,362 | -6.11% | -$2.54M | 0.03 | |
Capital World Investors | $36.39M | 0.58 | 839,463 | 0% | +$0 | 0.01 | |
Squarepoint Ops LLC | $32.3M | 0.51 | 745,173 | +1,158.65% | +$29.74M | 0.12 | |
Farallon Capital | $31.82M | 0.5 | 734,000 | -52.8% | -$35.59M | 0.22 | |
Royal Bank of Canada | $31.74M | 0.5 | 732,237 | -5.43% | -$1.82M | 0.01 | |
Northern Trust | $30.01M | 0.47 | 692,247 | +0.62% | +$184,714.35 | 0.01 | |
JPMorgan Chase | $27.35M | 0.43 | 630,979 | -32.95% | -$13.44M | <0.01 | |
Bank of America | $26.28M | 0.42 | 606,298 | +33.23% | +$6.56M | <0.01 | |
BNY Mellon | $25.3M | 0.4 | 583,589 | -8.96% | -$2.49M | 0.01 | |
Millennium Management LLC | $25.28M | 0.4 | 583,179 | -34.5% | -$13.31M | 0.02 | |
Wells Fargo | $25.32M | 0.4 | 584,158 | -1.7% | -$437,487.69 | 0.01 | |
Barclays | $25.03M | 0.4 | 577,387 | -10.41% | -$2.91M | 0.01 | |
Jacobs Levy Equity Management | $24.79M | 0.39 | 571,763 | +12.21% | +$2.7M | 0.11 | |
Nomura Holdings | $20.41M | 0.32 | 470,837 | -3.75% | -$795,559.20 | 0.18 | |
AXA | $20.15M | 0.32 | 464,815 | +0.02% | +$3,207.90 | 0.06 | |
Pinnacle Associates, Ltd. | $19.93M | 0.32 | 459,758 | +0.17% | +$33,769.65 | 0.32 | |
Invesco | $19.2M | 0.3 | 442,887 | +115.1% | +$10.27M | <0.01 | |
Nuveen | $18.34M | 0.29 | 423,030 | +30.56% | +$4.29M | 0.01 | |
Artisan Partners | $18.07M | 0.29 | 416,729 | New | +$18.07M | 0.03 | |
Eversept Partners LP | $16.32M | 0.26 | 376,438 | +15.95% | +$2.24M | 1.23 | |
Hudson Bay Capital Management LP | $14.54M | 0.23 | 335,500 | +131.38% | +$8.26M | 0.15 | |
C Worldwide Group Holding A S | $13.01M | 0.21 | 300,000 | 0% | +$0 | 0.15 | |
Baillie Gifford Co | $12.82M | 0.2 | 295,683 | -0.94% | -$121,380.01 | 0.01 | |
Liontrust Investment Partners LLP | $12.51M | 0.2 | 288,544 | +1.61% | +$197,806.04 | 0.18 | |
Point72 Asset Management | $12.42M | 0.2 | 286,602 | -70.42% | -$29.57M | 0.02 | |
Verition Fund Management Llc | $12.4M | 0.2 | 285,947 | +100.17% | +$6.2M | 0.14 | |
Cubist Systematic Strategies | $12.04M | 0.19 | 277,791 | +39.26% | +$3.39M | 0.11 | |
Assenagon Asset Management S.A. | $11.76M | 0.19 | 271,263 | +47.1% | +$3.77M | 0.03 |